Biogen Says Health Canada Approves Updates To TYSABRI Product Monograph – NASDAQ

Patients who are anti-JCV antibody positive, have received prior immunosuppressant or IS therapy and have received treatment with TYSABRI for more than two years have the highest risk of developing PML.